Affibody’s proprietary technology platform has a proven track record of developing candidate drugs targeting severe diseases. We choose to selectively collaborate with companies that have extensive knowledge in relevant therapeutic areas and a significant commitment in drug development and commercialization of biologics.
Izokibep partnerships
To achieve maximum development speed and rapid future market penetration, the global development of the company’s most advanced drug candidate, izokibep, is being conducted in collaboration with partners. In 2020 and 2021, respectively, Affibody partnered with Inmagene Biopharmaceuticals and ACELYRIN for the development of izokibep. Together, the company triad leads the development of izokibep in several autoimmune diseases where the protein IL-17A plays a foundational role.
